Biogen to Present New Aduhelm Data at Upcoming Alzheimer’s Conference

The annual Clinical Trials on Alzheimer’s Disease conference (CTAD) is scheduled for November 9-12, and Biogen announced plans to present data on its portfolio, including its controversial Aduhelm (aducanumab).